Clinical and epidemiological study of disease caused by Mycobacterium kansasii in the metropolitan area of Bilbao, Spain;Estudio clinicoepidemiológico de la enfermedad por Mycobacterium kansasii en el área urbana de Bilbao

Archivos de Bronconeumologia

Volumn 41, Issue 4, 2005, Pages 189-196

  Leal Arranz, M V ^a,b   Gaafar, A ^a   Unzaga Baranano M J ^a   Crespo Notario, J A ^a   Cisterna Cancer R ^a   Garcia Cebrian F ^a  

^a HOSPITAL DE BASURTO   (Spain)

^b NONE   (Spain)

Author keywords

Epidemiology; Human immunodeficiency virus; M. kansasii

Indexed keywords

CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLASSIFICATION; CLINICAL FEATURE; CLONE; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DUODENUM ULCER; EPIDEMIOLOGICAL DATA; FEMALE; FEVER; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LUNG CAVITATION; LUNG INFILTRATE; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MICROBIOLOGICAL EXAMINATION; MOLECULAR BIOLOGY; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; RADIOGRAPHY; RESPIRATORY TRACT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; REVIEW; SEX RATIO; SILICOSIS; SMOKING; SPECIES DIFFERENTIATION; SYMPTOM; TUBERCULOSIS; URBAN AREA; WEIGHT REDUCTION;

EID: 17844377022     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13073168     Document Type: Article

References (32)

1. Collins CH, Grange JM, Yates MD. Mycobateria in water. J Applied Bacteriology. 1984;57:193-211.
2. Chobot S, Maliys J, Sebyakovya H, Pelikyan M, Zatloukal O, Paliycka P, et al. Endemic incidence of infections caused by Mycobacterium kansasii in the Karviná District in 1968-1995. Centr Eur J Publ Health. 1997;4:164-73.
3. Slosárek M, Kubín M, Pokorny J. Water as a possible factor of transmission in mycobacterial infections. Centr Eur J Publ Health. 1994;2:103-5.
4. Steadham JE. High-catalase strains of Mycobacterium kansasii isolated from water in Texas. J Clin Microbiol. 1980;11:496-8.
5. Reparaz J. Enfermedad por Mycobacterium kansasii. Enferm Infecc Microbiol Clin. 1999;17:85-90.
6. Sistema de Información Microbiológica de la CAPV. Disponible en: www.osasun.ejqv.euskadi.net
7. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156:S1-S25.
8. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:1-19.
9. Lillo M, Orengo S, Cernoch P, Harris RL. Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. Rev Infect Dis. 1990;12:760-7.
10. Devallois A, Goh KS, Rastogi N. Rapid identification of mycobacteria to species level by PCR-restriction fragment length polymorphism analysis of the hsp65 gene and proposition of an algorithm to differentiate 34 mycobacterial species. J Clin Microbiol. 1997;35:2969-73.
11. Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol. 1993;31:175-8.
12. Savelkoul PH, Aarts HJ, de Haas J, Dijkshoorn L, Duim B, Otsen M, et al. Amplified-fragment length polymorphism analysis: the state of art. J Clin Microbiol. 1999;37:3083-91.
13. Vos P, Hogers R, Bleeker M, Reijans M, Van De Lee H, Hormes M, et al. AFLP: a new technique for DNA fingerprinting. Nucleic Acids Research. 1995;23:4407-14.
14. Alcaide F, Benítez MA, Martín R. Epidemiology of Mycobacterium kansasii. Ann Intern Med. 1999;131:310.
15. Alcaide F, Richter I, Bernasconi C, Springer B, Hagenau C, Schulze-Róbbecke R, et al. Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. J Clin Microbiol. 1997:1959-64.
16. Gaafar AAH. Mycobacterium kansasii. Estudio epidemiológico mediante técnicas de biología molecular [Tesina].
17. Taillard C, Greub G, Weber R, Pfyffer GE, Bodmer T, Zimmerli S, et al. Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey. J Clin Microbiol. 2003;41:1240-4.
18. Bloch KC, Vugia DJ, Reingold AL. Epidemiology of Mycobacterium kansasü. Ann Intern Med. 1999;131:311.
19. Bamberger DM, Driks MR, Gupta MR, O'Connnor MC, Jost PM, Eihart RE. Mycobacterium kansasii among patients infected with human immunodeficiency virus in Kansas City. Clin Infect Dis. 1994;18:395-400.
20. Carpenter JL, Parks JM. Mycobacterium kansasii infections in patients positive for human immunodeficiency virus. Rev Infect Dis. 1991;13:789-96.
21. Evans AJ, Crisp AJ, Hubbard RB, Colville A, Evans SA, Johnston IDA. Pulmonary Mycobacterium kansasii infection: comparison of radiological appearances with pulmonary tuberculosis. Thorax. 1996;51:1243-7.
22. Penny ME, Cole RB. Two cases of Mycobacterium kansasii infection occurring in the same household. Tubercle. 1982;63:129-31.
23. Bloch KC, Zwerling L, Pletcher MJ, Hahn JA, Gerberding JL, Ostroff SM. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med. 1998;129:698-704.
24. Evans SA, Colville A, Evans AJ, Crisp AJ, Johnston IDA. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. Thorax. 1996;51:1248-52.
25. Collins CH, Yates MD. Infection and colonisation by Mycobacterium kansasii and Mycobacterium xenopi: aerosols as a possible source? Public Health Laboratory Service, Regional Centre for Tuberculosis Bacteriology, Dulwich Hospital, London. J Infect. 1983;8:178-9.
26. Corbett EL, Blumberg L, Churchyard GJ, Moloi N, Mallory K, Clayton T, et al. Nontuberculous mycobacteria. Defining disease in a prospective cohort of South African miners. Am J Respir Crit Care Med. 1999;160:15-21.
27. Martínez Moragón E, Menéndez R, Santos M, Lorente R, Marco V. Enfermedad pulmonar por micobacterias ambientales oportunistas en pacientes sin infección por virus de la inmunodeficiencia humana. Factores de riesgo, clínica, diagnóstico y evolución. Arch Bronconeumol. 1996;32:170-5.
28. Garrós J, García Cebrián F, Martín G, Lorza JJ, Ruiz de Gordejuela E. Enfermedad pulmonar por Mycobacterium kansasii. Análisis de 39 casos. Arch Bronconeumol. 2001;37:27-34.
29. Canetti G. Mesures de la sensibilité du bacille tuberculeux aux drogues antibacilarires par le methode des proportions. Rev Tuberc. 1963;27:217-72.
30. Sauret J, Hernández-Flix S, Castro E, Ausina V, Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii; results of 18 vs 12 months chemotherapy. Tuber Lung Dis. 1995;76:583.
31. Sauret J, Hernández S. Tratamiento actual de las micobacteriosis. Med Clin (Barc), 1990;95:64-6.
32. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax. 1994;49:442-5.